Mankind Pharma Q3 FY26: Revenue 2632 cr, PAT 449 cr

Exceptional ItemEmphasis Of MatterResults RestatedResults View source PDF Explain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.5%Reaction day

₹2162.50

prior close

₹2199.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.6%-4.1% vs market

Pharmaceuticals peers, median of 155sector+0.2%-3.7% vs sector

On the reaction day the stock moved 4.1 pts less than Nifty Midcap 150 and 3.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.9

10m

-3.5

15m

-4.0

30m

-4.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.5+0.6-4.1+0.2-3.7

Next day

-3.6+0.3-3.9-0.4-3.2

-4.7+0.3-5.0-1.1-3.6

-3.6+1.8-5.5+0.7-4.3

-4.2+2.2-6.4+1.3-5.5

-3.5+2.3-5.8+1.5-5.0

-4.7+0.1-4.8+0.3-5.1

15d

+0.1+0.4-0.3-2.6+2.7

+1.9-4.0+5.9-5.1+7.0

-6.8-8.1+1.3-7.9+1.1

+4.9+1.3+3.5+0.7+4.2

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited Q3 and 9M FY26 results (quarter ended Dec 31, 2025). Standalone revenue Rs 2,632.68 cr (up 8.3% YoY from Rs 2,431.15 cr), 9M revenue Rs 7,839.36 cr (up 6.1%). Standalone Q3 PAT Rs 449.47 cr, up 10.9% YoY. Consolidated Q3 revenue Rs 3,567.20 cr, PAT Rs 413.88 cr. Exceptional items of Rs 83.42 cr standalone due to new Labour Code adoption and stamp duty on BSV acquisition. Comparatives restated for BSV business acquisition. Auditor flagged pending Income tax appeals (Section 132) but no material impact expected.

Likely market impact

Modest revenue growth, PAT up about 11%. One-time exceptional charge from Labour Code and stamp duty. BSV acquisition integrated. Tax disputes pending appeal.